NCT04873323已完成1 期
A Study to Evaluate the Effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs
研究概览
简要总结
A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Japanese Males or females aged 20 years or older but less than 40 years at the time of informed consent
- •those with a BMI of 18.5 in male (17.6 in female) or more and less than 25.0 and a body weight of 40.0 kg or more at screening test
- •those whose pulse rate measured by standard 12-lead ECG is 50 beats/min or more but no more than 90 beats/min at screening test and at the time before administration of investigational drug in period 1
- •those who are judged eligible to participate in the study by the principal investigator or sub-investigator based on the results of screening test and test conducted before administration of investigational drug in period
- •However, if who showed abnormal findings but not clinically significant, they can be enrolled in clinical trials based on comprehensive consideration of medical viewpoints by the principal investigator or subinvestigator.
- •those who are able to receive the explanation before participating in the study, understand the content of the study, and provide written informed consent by the subjects themselves.
排除标准
- •Subjects who have any disease and are not considered healthy subjects based on the medical judgment of the principal investigator or sub-investigator.
- •Subjects with a medical history considered inappropriate for participation in the study, including respiratory, cardiovascular, gastrointestinal, hepatic, renal, urological, endocrine, metabolic, hematological, immune, skin, neurological, and psychiatric diseases.
- •Subjects with a history of drug allergy or food allergy.
- •Subjects with a history of hypersensitivity to moxifloxacin or other quinolone antimicrobials
- •Subjects with risk factors or with a history of risk factors for aortic aneurysm, aortic dissection (such as Marfan syndrome)
- •Subjects with significant allergic predisposition (such as asthma requiring medical treatment)
- •Subjects with congenital disease, heart disease, or a history of heart disease
- •Subjects with risk factors or with a history of risk factors for torsade de pointes (TdP) (heart failure, hypokalemia, family history of long QT syndrome, etc.)
- •Subjects with a history of unconscious seizures suspected of involving TdP.
- •Subjects with waveforms difficult to assess for QTc interval prolongation in standard 12-lead ECG at screening and the timing before administration of investigational product in period 1 (drift, electromyography contamination, T-wave geometry, marked sinus arrhythmia, frequent premature beats, etc.)
- •Subjects with QTcF(Fridericia correction method) of at least 450 msec in men and at least 470 msec in women in standard-12-lead ECG at screening test and at the time before administration of investigational product in period
- •Subjects with suicidal ideation, suicide attempt on the Colombian Suicide Assessment Scale (C-SSRS) on Day-1 or a history of suicide attempt within the previous 5 years.
- •Other protocol defined inclusion criteria could apply
研究组 & 干预措施
TS-142 10 mg
Experimental
TS-142 therapeutic dose oral tablet (low dose)
干预措施: TS-142 (Drug)
TS-142 30 mg
Experimental
Description: TS-142 supratherapeutic dose oral tablet (high dose)
干预措施: TS-142 (Drug)
Moxifloxacin 400 mg
Experimental
Moxifloxacin tablet
干预措施: Moxifloxacin (Drug)
Placebo
Experimental
Placebo oral tablet
干预措施: Placebo (Drug)
结局指标
主要结局
QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs
时间窗: Up to 24 hours postdose during each period
Difference (ΔΔQTc) in change from baseline (ΔQTc) in QTc interval at each time point in each group compared with the placebo group
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineSchizophreniaSchizoaffective DisorderNCT00791622Johnson & Johnson Pharmaceutical Research & Development, L.L.C.110
已完成
1 期
Study to Evaluate the QT / QTc Interval Prolongation Potential of VericiguatCoronary Artery DiseaseNCT03504982Bayer74
已完成
1 期
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male SubjectsAmount of NKTR-118 in BloodVariation in the Heart's Electrical CycleNCT01325415AstraZeneca45
已完成
1 期
A QT/QTc Evaluation Study of TS-142 in Healthy Adult SubjectsInsomniaJPRN-jRCT2071210018Mita Seiji48
已完成
1 期
A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy ParticipantsHealthyNCT02658825Janssen Research & Development, LLC66